IDM Pharma (IDMI) Receives Special Protocol Assessment from FDA for Phase 2/3 Trial of Bexidem
Tweet Send to a Friend
IDM Pharma Inc. (NASDAQ: IDMI) received a Special Protocol Assessment (SPA) from the FDA for the planned Phase 2/3 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
